DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Operating Cash Flow
Cash generated by the company's core business operations during the period.
DBV Technologies S.A.NASDAQ: DBVT
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $49.1M (cash outflow) rose 149.6% year over year, ahead of the +68.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 39.6% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +149.6% holds above the trailing-twelve-month pace of +68.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (121.18M) USD
- Year-over-year change
- -16.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (121.18M) | -16.0% |
| FY2024 | 2024-12-31 | (104.47M) | -31.2% |
| FY2023 | 2023-12-31 | (79.65M) | -43.0% |
| FY2022 | 2022-12-31 | (55.7M) | +48.5% |
| FY2021 | 2021-12-31 | (108.24M) | — |
Operating Cash Flow vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 operating cash flow of $150.61M is the 2nd largest of the 11 companies compared; the peer median is $71.06M.
- Its year-over-year change of +68.4% is the 2nd highest of 10, against a peer median of +17.6%.
- Over three fiscal years its annual growth of +29.6% compares with a peer median of +21.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $183.1M | +31.0% | +17.0% | — | |
| LTM Mar 2026 | $150.61M | +68.4% | +29.6% | — | |
| LTM Mar 2026 | $131.28M | +51.1% | +60.1% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $110M | +45.9% | +78.0% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.99M | +11.4% | +21.8% | — |
| LTM Mar 2026 | $71.94M | -10.5% | +2.6% | 199819.4% | |
| LTM Mar 2026 | $70.18M | +12.1% | +13.6% | 1826.7% | |
| LTM Mar 2026 | $62.3M | +17.6% | +36.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $51.63M | — | +134.6% | — |
| LTM Mar 2026 | $37.91M | -230.1% | -22.9% | 55.7% | |
| LTM Mar 2026 | $25.51M | +182.6% | — | 11.9% | |
| Peer median (excluding DBVT) | $71.06M | +17.6% | +21.8% | 941.2% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.81M) | (96.27M) | (72.73M) | (113.92M) | (146.95M) |
| Depreciation & Amortization | 8.38M | 13.16M | (14M) | (925K) | 3.19M |
| Deferred Income Tax | 184K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.12M | 5.03M | 6.02M | 4.62M | 5.39M |
| Change in Working Capital | (22.77M) | 22.32M | 953K | 5.75M | 1.34M |
| Accounts Receivables | 2.15M | 0 | 0 | 0 | 0 |
| Inventory | (16.18M) | 0 | 0 | 0 | (16.11M) |
| Accounts Payables | (7.56M) | 3.46M | 8.42M | 272K | 15.83M |
| Other Working Capital | (1.19M) | 18.86M | (7.47M) | 5.48M | 1.62M |
| Other Non-Cash Items | 656K | 66K | 99K | (3K) | 15.84M |
| Operating Cash Flow | (108.24M) | (55.7M) | (79.65M) | (104.47M) | (121.18M) |
| Capital Expenditures | (918K) | (754K) | (677K) | (2.34M) | (533.64K) |
| Acquisitions (Net) | 511.01K | 7.61K | 0 | 0 | 0 |
| Purchases of Investments | (119K) | (123K) | (285K) | 0 | 0 |
| Sales of Investments | (511.01K) | 770K | 154K | 0 | 0 |
| Other Investing Activities | 604K | (611) | (131K) | 1.58M | (829.34K) |
| Investing Cash Flow | (433K) | (100K) | (808K) | (757K) | (1.37M) |
| Debt Repayment | (582.92K) | (474K) | 0 | 0 | 0 |
| Common Stock Issued | 978K | 194.59M | 6.92M | 634K | 277.04M |
| Common Stock Repurchased | 0 | 0 | (154K) | (47K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (121.08K) | (20K) | 0 | 0 | (854.56K) |
| Financing Cash Flow | 274K | 194.1M | 6.77M | 587K | 276.18M |
| Effect of Forex Changes | (10.65M) | (6.5M) | 5.87M | (4.27M) | 8.08M |
| Net Change in Cash | (119.05M) | 131.9M | (67.83M) | (108.91M) | 161.71M |
| Free Cash Flow | (109.16M) | (56.45M) | (80.33M) | (106.82M) | (121.18M) |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.